• News

"Precision Medicine - Personalizing Treatment For Multiple Myeloma" - Andrea S. Blevins Primeau, PhD

  • Cancer Therapy Advisor
  • New York, NY
  • (October 01, 2018)

A precision medicine platform incorporating RNA sequencing and copy number alterations (CNA) identified targeted treatment options for patients with relapsed/refractory multiple myeloma (MM), according to a study published in JCO Precision Oncology. “MM is a genetically complex disease and the large mutational heterogeneity observed across patients suggests that the employment of a personalized therapeutic approach is likely to improve outcomes,” said Alessandro Lagana, PhD, assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai, and an author of the study. “The main difference from other molecular profiling tests is that they are based on DNA sequencing, while we also integrate analysis of the RNA — which enables the identification of more therapeutic options that would not be possible to select based solely on genetic mutations,” Dr Lagana said.

- Alessandro Lagana, PhD, Assistant Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

Learn more